Barker Colin M, Reardon Michael J
Department of Cardiology and Reardon Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX 77030, USA.
Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA.
Future Cardiol. 2018 Sep;14(5):367-373. doi: 10.2217/fca-2018-0044. Epub 2018 Aug 24.
Transcatheter aortic valve replacement has become an acceptable alternative to surgical aortic valve replacement in patients who are intermediate to high risk for surgery. The Lotus valve system (Boston Scientific, MA, USA) is an unique, mechanically expanded device. The system includes a braided nitinol frame and an adaptive seal to minimize paravalvular regurgitation. REPRISE III illustrated that among high-risk patients the use of the Lotus valve compared with a self-expanding valve did not result in inferior outcomes for the primary safety end point or the primary effectiveness end point. Future investigation of the Lotus valve system includes the use in low to intermediate risk patients with aortic stenosis as well as those with bicuspid aortic valves and mitral annular calcification.
对于手术风险处于中高程度的患者,经导管主动脉瓣置换术已成为可接受的外科主动脉瓣置换术替代方案。Lotus瓣膜系统(美国马萨诸塞州波士顿科学公司)是一种独特的机械扩张装置。该系统包括一个编织镍钛诺框架和一个自适应密封件,以尽量减少瓣周反流。REPRISE III研究表明,在高危患者中,与自膨胀瓣膜相比,使用Lotus瓣膜在主要安全性终点或主要有效性终点方面并未导致较差结果。Lotus瓣膜系统未来的研究包括应用于主动脉瓣狭窄的低至中度风险患者以及患有二叶式主动脉瓣和二尖瓣环钙化的患者。